Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Lips, Irene M ^a   van der Heide, Uulke A ^b   Haustermans, Karin ^c   van Lin, Emile N J T ^d   Pos, Floris ^b   Franken, Stefan P G ^a   Kotte, Alexis N T J ^a   van Gils, Carla H ^a   van Vulpen, Marco ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Katholieke Universiteit   (Belgium)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

External beam radiotherapy; Flame trial; Microboost; Prostate cancer

Indexed keywords

ADULT; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DOSE RESPONSE; EXTERNAL BEAM RADIOTHERAPY; FIDUCIAL MARKER; FOCAL LESION ABLATIVE MICROBOOST; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STUDY DESIGN; TREATMENT DURATION; TUMOR ABLATION; TUMOR LOCALIZATION; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MULTICENTER STUDY; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; RADIATION DOSE;

AGED; CLINICAL PROTOCOLS; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; SINGLE-BLIND METHOD;

EID: 82655170568     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-255     Document Type: Article

References (74)

1. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997, 349(9056):906-910.
2. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53(5):1097-1105.
3. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD, , . Scandinavian Prostate Cancer Group Study 7, Swedish Association for Urological Oncology 3 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373(9660):301-308. Scandinavian Prostate Cancer Group Study 7, Swedish Association for Urological Oncology 3.
4. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24(13):1990-1996.
5. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239.
6. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK, . RT01 collaborators Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8(6):475-487. RT01 collaborators.
7. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53(5):1111-1116.
8. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2003, 57(2):391-401.
9. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, Scardino PT, Zelefsky MJ. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007, 69(1):62-69.
10. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, Manfredi R, Dinapoli N, Digesu' C, Smaniotto D. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53(3):595-599.
11. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002, 20(15):3199-3205.
12. Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 71(1):16-22.
13. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004, 100(3):538-543.
14. Lips IM, van der Heide UA, Kotte AN, van Vulpen M, Bel A. Effect of translational and rotational errors on complex dose distributions with off-line and on-line position verification. Int J Radiat Oncol Biol Phys 2009, 74(5):1600-1608.
15. van Lin EN, Futterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, Huisman HJ, Scheenen TW, Witjes JA, Leer JW, Barentsz JO, Visser AG. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006, 65(1):291-303.
16. Miralbell R, Molla M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, Sanz S, Ares C, Jorcano S, Linero D, Escude L. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys 2010, 78(1):50-57.
17. Gaudet M, Vigneault E, Aubin S, Varfalvy N, Harel F, Beaulieu L, Martin AG. Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis. Int J Radiat Oncol Biol Phys 2010, 77(1):153-159.
18. Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72(3):799-807.
19. De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, De Neve W. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 2005, 75(3):325-333.
20. Singh AK, Guion P, Sears-Crouse N, Ullman K, Smith S, Albert PS, Fichtinger G, Choyke PL, Xu S, Kruecker J, Wood BJ, Krieger A, Ning H. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2007, 2:36.
21. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L, , . ESTRA/EAU Urological Brachytherapy Group, EORTC Radiotherapy Group ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000, 57(3):315-321. ESTRA/EAU Urological Brachytherapy Group, EORTC Radiotherapy Group.
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982, 5(6):649-655.
23. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 61(4):1019-1034.
24. Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. Int J Radiat Oncol Biol Phys 2000, 48(3):643-647.
25. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37(1):3-11.
26. van der Wielen GJ, van Putten WL, Incrocci L. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2007, 68(2):479-484.
27. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999, 85(11):2460-2468.
28. Turner SL, Adams K, Bull CA, Berry MP. Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology 1999, 54(1):124-129.
29. Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, Francis L, Kramar A, D'Este C, Bill D. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 2005, 77(2):117-125.
30. Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Valdagni R. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 2007, 67(5):1401-1410.
31. Moman MR, van der Heide UA, Kotte AN, van Moorselaar RJ, Bol GH, Franken SP, van Vulpen M. Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 2010, 96(1):38-42.
32. van der Heide UA, Kotte AN, Dehnad H, Hofman P, Lagenijk JJ, van Vulpen M. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol 2007, 82(1):38-45.
33. Nederveen AJ, van der Heide UA, Hofman P, Welleweerd H, Lagendijk JJ. Partial boosting of prostate tumours. Radiother Oncol 2001, 61(2):117-126.
34. Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, van der Heide UA, van Vulpen M. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 2008, 3:15.
35. Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999, 43(1):57-66.
36. Usmani N, Sloboda R, Kamal W, Ghosh S, Pervez N, Pedersen J, Yee D, Danielson B, Murtha A, Amanie J, Monajemi T. Can Images Obtained with High Field Strength Magnetic Resonance Imaging Reduce Contouring Variability of the Prostate?. Int J Radiat Oncol Biol Phys 2010, 80(3):728-734.
37. Groenendaal G, van den Berg CA, Korporaal JG, Philippens ME, Luijten PR, van Vulpen M, van der Heide UA. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010, 95(2):185-190.
38. van der Heide UA, Korporaal JG, Groenendaal G, Franken SP, van Vulpen M. Functional MRI for tumor delineation in prostate radiation therapy. Imaging Med 2011, 3(2):219-231.
39. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002, 16(4):407-422.
40. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004, 20(4):654-661.
41. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology 1999, 213(2):473-480.
42. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65(4):965-974.
43. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13(3):176-181.
44. Hornbrook MC, Goodman MJ. Assessing relative health plan risk with the RAND-36 health survey. Inquiry 1995, 32(1):56-74.
45. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376.
46. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996, 5(2):212-222.
47. Litwin MS, Fitzpatrick JM, Fossa SD, Newling DW. Defining an international research agenda for quality of life in men with prostate cancer. Prostate 1999, 41(1):58-67.
48. Nout RA, van de Poll-Franse LV, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, Pras B, van Putten WL, Creutzberg CL. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011, 29(13):1692-1700.
49. Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, Winer E, Casey R, Bennett S, Cohen HJ, Muss HB. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: A companion study to cancer and leukemia group B 49907. J Clin Oncol 2011, 29(8):1022-1028.
50. Inoue S, Shiina H, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M, Usui T. Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in japanese men, using general and disease-specific measures. BJU Int 2009, 104(8):1077-1084.
51. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24(13):1990-1996.
52. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323(7321):1123-1124.
53. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, . Quality of Life Committee of the NCIC CTG Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005, 41(2):280-287. Quality of Life Committee of the NCIC CTG.
54. Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Wasserman T, Bruner DW. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 2009, 27(34):5816-5822.
55. Mutanga TF, de Boer HC, van der Wielen GJ, Hoogeman MS, Incrocci L, Heijmen BJ. Margin Evaluation in the Presence of Deformation, Rotation, and Translation in Prostate and Entire Seminal Vesicle Irradiation with Daily Marker-Based Setup Corrections. Int J Radiat Oncol Biol Phys
56. Meijer GJ, de Klerk J, Bzdusek K, van den Berg HA, Janssen R, Kaus MR, Rodrigus P, van der Toorn PP. What CTV-to-PTV margins should be applied for prostate irradiation? Four-dimensional quantitative assessment using model-based deformable image registration techniques. Int J Radiat Oncol Biol Phys 2008, 72(5):1416-1425.
57. Rijkhorst EJ, Lakeman A, Nijkamp J, de Bois J, van Herk M, Lebesque JV, Sonke JJ. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects. Int J Radiat Oncol Biol Phys 2009, 75(4):1254-1260.
58. Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 2007, 69(2):419-425.
59. Pinkawa M, Asadpour B, Gagel B, Piroth MD, Holy R, Eble MJ. Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder. Int J Radiat Oncol Biol Phys 2006, 64(3):856-861.
60. Lips IM, Kotte AN, van Gils CH, van Leerdam ME, van der Heide UA, van Vulpen M. Influence of Antiflatulent Dietary Advice on Intrafraction Motion for Prostate Cancer Radiotherapy. Int J Radiat Oncol Biol Phys
61. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10(3):223-232.
62. Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, Kernen KM, Hollander JB, Gonzalez JA, Martinez AA, Vicini FA, Kestin LL. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65(4):999-1007.
63. Lips I, Dehnad H, Kruger AB, van Moorselaar J, van der Heide U, Battermann J, van Vulpen M. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 2007, 69(3):656-661.
64. Lips IM, van Gils CH, van der Heide UA, Kruger AE, van Vulpen M. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. BJU Int 2009, 103(6):762-767.
65. Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, Bonnaud-Antignac A, Lisbona A, Mahe MA, Supiot S. No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010, 77(4):1053-1059.
66. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176(4 Pt 1):1415-1419.
67. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999, 44(4):921-929.
68. Xia P, Pickett B, Vigneault E, Verhey LJ, Roach M. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001, 51(1):244-254.
69. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009, 30(2):327-334.
70. van Vulpen M, van den Berg CA, Moman MR, van der Heide UA. Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiother Oncol 2009, 93(2):180-184.
71. De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 2010, 194(6):1427-1433.
72. Kim CK, Park BK, Park W, Kim SS. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 2010, 35(2):246-252.
73. Rouviere O. MR assessment of recurrent prostate cancer after radiation therapy. Radiology 2007, 242(2):635-6. author reply 636-7.
74. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70(2):425-430.